INTRODUCTION
============

In traumatic and ischemic injury, neurons die acutely in the injury core, and slowly in the penumbra. Thus, slowly occurring, delayed neuronal death has been a therapeutic target for reducing overall neuronal injury. Brain inflammation has long been considered to cause delayed neuronal death. In culture, neurons die in the presence of microglia (brain macrophages) challenged with inflammatory stimulators, such as lipopolysaccharide (LPS), interferon-γ and β-amyloid; similar results have been reported in the ischemic brain ([@b3-molcell-37-4-345-10]; [@b9-molcell-37-4-345-10]; [@b19-molcell-37-4-345-10]; [@b35-molcell-37-4-345-10]; [@b36-molcell-37-4-345-10]). Among the potential toxic inflammatory mediators suggested to be derived from microglia are nitric oxide (NO), tumor necrosis factor (TNF)-α, and cyclooxygenase (COX) products ([@b3-molcell-37-4-345-10]; [@b9-molcell-37-4-345-10]; [@b19-molcell-37-4-345-10]; [@b35-molcell-37-4-345-10]; [@b36-molcell-37-4-345-10]). However, recently, we and others have reported that inflammatory responses in the injured brain and spinal cord are not neurotoxic; instead, brain inflammation is neuroprotective and functions to repair the injured brain ([@b12-molcell-37-4-345-10]; [@b13-molcell-37-4-345-10]; [@b14-molcell-37-4-345-10]; [@b15-molcell-37-4-345-10]; [@b25-molcell-37-4-345-10]; [@b40-molcell-37-4-345-10]; [@b43-molcell-37-4-345-10]). Therefore, there may be another mechanism responsible for causing secondary neuronal death.

Astrocytes, which constitute the majority of cells in the brain, support the well-being and function of neurons. Astrocytes regulate the microenvironment of the brain. For example, excitatory amino acid transporter (EAAT)-1/2 and the inward rectifying potassium channel Kir4.1 maintain extracellular homeostasis through uptake of glutamate and potassium ions, respectively ([@b28-molcell-37-4-345-10]; [@b34-molcell-37-4-345-10]). Aquaporin-4 (AQP4) expressed in astrocytes regulates extracellular water content ([@b39-molcell-37-4-345-10]). Astrocytes also provide neurons with glucose and neurotrophic factors, and protect neurons from oxidative stress ([@b1-molcell-37-4-345-10]; [@b4-molcell-37-4-345-10]; [@b29-molcell-37-4-345-10]; [@b41-molcell-37-4-345-10]). It has been reported that selective ablation of reactive astrocytes exacerbates traumatic neuronal damage, and that transplantation of astrocytes diminishes brain damage ([@b8-molcell-37-4-345-10]; [@b27-molcell-37-4-345-10]). Loss of EAAT2/GLT-1 has been found in human amyotrophic lateral sclerosis (ALS) ([@b31-molcell-37-4-345-10]; [@b32-molcell-37-4-345-10]), and brain damage due to ischemia is aggravated in AQP4-deficient mice ([@b10-molcell-37-4-345-10]; [@b38-molcell-37-4-345-10]; [@b45-molcell-37-4-345-10]). Recently, we reported that the delayed neuronal death in contusion-induced spinal cord injury is spatially and temporally correlated with astrocyte death, suggesting that loss of astrocyte function is a critical cause of neuronal death ([@b25-molcell-37-4-345-10]).

In this study, we analyzed astrocyte behavior and neuronal death in kainic acid (KA)- and N-ethyl-D-aspartic acid (NMDA)-induced injury models. Interestingly, the former induced dramatic secondary neuronal death whereas the latter did not, despite a similar inflammatory response in the two models. These results suggest that there is little relationship between brain inflammation and secondary neuronal death. Importantly, loss of astrocyte support appeared to cause secondary neuronal death. These results suggest that protection of astrocytes and/or maintenance of astrocyte function could be new therapeutic strategies for protecting neurons from injury.

MATERIALS AND METHODS
=====================

Stereotaxic surgery and drug injection
--------------------------------------

Male Sprague-Dawley rats (230--250 g, 7 week old) were anesthetized by injection of chloral hydrate (360 mg/kg, i.p.) and positioned in a stereotaxic apparatus (David Kopf Instruments, USA). KA (20 nmole) and NMDA (100 nmole) in 2 μl sterile phosphate-buffered saline (PBS), were unilaterally administered into the cortex (AP, +0.7 mm; ML, −2.0 mm; DV, −2.0 mm from bregma), according to the atlas of Paxinos and Watson (Paxinos and Watson, 2005). All drugs were purchased from Sigma (USA) and were prepared in PBS, according to the manufacturers' instructions. All animals were injected using a Hamilton syringe equipped with a 30-gauge blunt needle attached to a syringe pump (KD Scientific, USA). Drugs were infused at a rate of 0.4 μl/min. After injection, the needle was held in place for an additional 5 min before removal. Contralateral sides and PBS-injected cortexes were used as controls. We collected data from at least 5 animals for each insult (PBS, NMDA, and KA) and each time point (3 h--7 days) after the first author of this study had been trained to obtain consistent damage areas in consistent regions with each drug.

Tissue preparation
------------------

For immunohistochemistry, rats were anesthetized and transcardially perfused with saline solution containing 0.5% sodium nitrate and heparin (10 U/ml), followed by 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.2) for tissue fixation. Brains were separated and post-fixed overnight at 4°C in 4% paraformaldehyde. Fixed brains were stored at 4°C in a 30% sucrose solution until they sank. Six separate series of 30-μm coronal brain sections were obtained using a sliding microtome (Microm, Germany) and stored in antifreeze stock solution (phosphate buffer pH 7.2 containing 30% glycerol, 30% ethylene glycol) at 4°C before use.

For RNA preparation, rats were anesthetized and transcardially perfused with saline solution only for 1 min. Brains were removed and sliced with a Rat Brain Slicer Matrix (1.0 mm slice intervals, RBM-4000C; ASI Instruments, USA) and a razor blade. A slice that included the needle injection spot was selected, and tissue blocks (2 × 2 × 2 mm) surrounding the needle track were collected and stored at −70°C until use.

Immunohistochemistry
--------------------

For 3, 3′-diaminobenzidine (DAB) staining, every sixth serial section was selected, rinsed three times with PBS, treated with 3% H~2~O~2~ for 5 min, and rinsed with PBS containing 0.2% Triton X-100 (PBST). Non-specific binding was blocked with 1% bovine serum albumen (BSA) in PBST. Sections were incubated over night at room temperature with primary antibodies. Information on the primary antibodies used is shown in [Table 1](#t1-molcell-37-4-345-10){ref-type="table"}. After rinsing in PBST, sections were incubated with biotinylated secondary antibodies (Vector Laboratories, USA) for 1 h and the avidin/biotin system (Vector Laboratories) for 1 h, and then visualized using a DAB solution (0.05% DAB and 0.003% hydrogen peroxide in 0.1 M phosphate buffer). For double staining of the neuronal nuclear marker NeuN and glial fibrillary acidic protein (GFAP), sections were stained with anti-NeuN antibodies and visualized using DAB (brown products). The same sections were then washed with PBS, treated with 1% BSA, incubated with anti-GFAP antibodies, and visualized using DAB and nickel sulfate (dark purple products). After staining, sections were mounted on gelatin-coated slides and examined under a bright field microscope (Olympus Optical, BX51, Japan). Bright field images were obtained using PictureFrame Application 2.3 software.

For immunofluorescence staining, sections were washed twice in PBS, treated with 1% BSA, and incubated with combinations of primary antibodies. For visualization, Alexa Fluor 488- or Alexa Fluor 555-conjugated secondary antibodies (1:600 dilution; Invitrogen, USA) were used. Counterstaining with 4′,6-diamidino-2-phenylindol (DAPI; Vector Laboratories, USA) was used to detect nuclei. Sections were analyzed under a confocal microscope (Carl Zeiss, Germany) with 40× water-and 63× oil-immersion objectives at 20°C. Images were captured using Confocal software (LSM Image Browser).

Quantitative real-time polymerase chain reaction (Q-PCR)
--------------------------------------------------------

Total RNA was isolated using an easy-BLUE RNA Extraction Kit (iNtRON, Korea), and cDNA was prepared using Super-Script III Reverse (Invitrogen, USA), according to the manufacturers' instructions. For Q-PCR, approximately 50 ng cDNA was analyzed using a KAPA SYBR FAST qPCR Kit (KAPA Biosystems, USA) and a Corbett Rotor-Gene 6000 real-time rotary analyzer (Corbett Research, Australia). Specific primers for interleukin (IL)-1β, inducible nitric oxide synthase (iNOS), TNF-α, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) used in Q-PCR are shown in [Table 2](#t2-molcell-37-4-345-10){ref-type="table"}. Q-PCR conditions were as follows: 95°C for 30 s, followed by 40 cycles of 95°C for 3 s (denaturation), 55°C for 20 s (annealing), and 72°C for 3 s (elongation). That a single product was amplified under the conditions used was confirmed by performing a melting curve analysis for each primer pair using a melt ramp of 72--95°C and raising the temperature by 1°C at each step (5 s/step). Amplified products were also verified by electrophoresis on 1.5% agarose gels with GelRed (Biotium, USA) staining. Results were normalized to GAPDH, used as a reference.

Image analysis
--------------

Photographs of the most damaged sections were taken and analyzed using Image J. At least 3--5 different animals for each experimental conditions were quantified.

Statistical analysis
--------------------

All values are expressed as means ± SEMs. The statistical significance of differences between mean values was assessed by Student's *t*-test using the Statistical Package for Social Sciences 8.0 (SPSS Inc., USA). All data presented in this study are representative of at least three independent experiments.

RESULTS
=======

Neurons underwent extensive delayed cell death in the KA-injected cortex, but not in the NMDA-injected cortex
-------------------------------------------------------------------------------------------------------------

Previously, we found that in contusion-induced spinal cord injury, astrocytes play a critical role in the secondary injury ([@b25-molcell-37-4-345-10]). Here, we investigated neuronal death in two brain injury models-KA- and NMDA-induced injury-based on the idea that astrocytes are vulnerable to KA but not to NMDA ([@b5-molcell-37-4-345-10]).

Interestingly, in the NMDA-injected cortex, local NeuN^+^ neuronal loss was detected at 3 h in the injection site, and the damaged area did not increase further up to 7 days ([Figs. 1B and 1D](#f1-molcell-37-4-345-10){ref-type="fig"}). We designated the area in which NeuN^+^ neurons disappeared at 3 h and 7 days as the 'a' region, and the area outside the 'a' region in the lateral direction as the 'b' region ([Fig. 1A](#f1-molcell-37-4-345-10){ref-type="fig"}). We also examined neuronal behavior in the KA-injected cortex. NeuN^+^ neurons were still present, although not healthy, in the injection site at 3 h, but disappeared throughout the entire hemisphere at 7 days ([Figs. 1C and 1D](#f1-molcell-37-4-345-10){ref-type="fig"}), indicating that KA injection induced extensive delayed neuronal death. In the PBS-injected brain, NeuN^+^ neurons were as healthy as those in the intact brain ([Fig. 1A](#f1-molcell-37-4-345-10){ref-type="fig"} vs. [Fig. 1C](#f1-molcell-37-4-345-10){ref-type="fig"}). These results demonstrate the presence and absence of delayed neuronal death in the KA- and NMDA-injected cortex, respectively.

Inflammatory responses occurred similarly in both NMDA-and KA-injected cortexes
-------------------------------------------------------------------------------

It has been suggested that brain inflammation that accompanies brain injury is harmful to neurons ([@b3-molcell-37-4-345-10]; [@b9-molcell-37-4-345-10]; [@b19-molcell-37-4-345-10]; [@b35-molcell-37-4-345-10]; [@b36-molcell-37-4-345-10]). Thus, we analyzed where inflammatory responses in NMDA- and KA- injected cortex occurred in relation to the presence and absence of progressive delayed neuronal death using the marker protein Iba-1 to identify resident microglia and blood-derived macrophages ([@b13-molcell-37-4-345-10]; [@b15-molcell-37-4-345-10]; [@b25-molcell-37-4-345-10]). Iba-1^+^ ramified resident microglia appeared to be dead or undergoing the process of dying at 3 h in both NMDA- and KA-injection cores ([Fig. 2A](#f2-molcell-37-4-345-10){ref-type="fig"}, [3](#f3-molcell-37-4-345-10){ref-type="fig"} h, region 'a'). However, at 7 days, NMDA and KA injection produced dramatically different results. In the NMDA model, Iba-1^+^ round cells appeared in the injection core ([Fig. 2A](#f2-molcell-37-4-345-10){ref-type="fig"}, NMDA 7 days, region 'a'), but Iba-1^+^ ramified cells were in the penumbra region ([Fig. 2A](#f2-molcell-37-4-345-10){ref-type="fig"}, NMDA 7 days, region 'b'). However, in the KA model, Iba-1^+^ round cells filled the entire hemisphere ([Fig. 2A](#f2-molcell-37-4-345-10){ref-type="fig"}, KA 7 days, regions 'a, b'). Previously, we reported that Iba-1^+^ round cells are monocytes infiltrated from blood to repair damaged brain ([@b13-molcell-37-4-345-10]; [@b15-molcell-37-4-345-10]; [@b17-molcell-37-4-345-10]; [@b25-molcell-37-4-345-10]). In the PBS-injected brain, Iba-1^+^ ramified resident microglia showed a morphology similar morphology to those in the intact brain ([Fig. 2A](#f2-molcell-37-4-345-10){ref-type="fig"}). Behavior of Iba-1^+^ cells in intact, NMDA-, KA, and PBS-injected brain at indicated times were quantified by measuring intensities of Iba-1 using Image J ([Fig. 2B](#f2-molcell-37-4-345-10){ref-type="fig"}). We measured mRNA expression of TNF-α and IL-1β increased in NMDA- and KA-models. Quantitative PCR analyses showed little difference in the inflammatory responses in the injury core ([Fig. 2C](#f2-molcell-37-4-345-10){ref-type="fig"}). mRNA expression of TNF-α and IL-1β increased at 3--12 h, and decreased at 1 day in both NMDA- and KA-injected cortexes compared to the PBS-injected cortex ([Fig. 2C](#f2-molcell-37-4-345-10){ref-type="fig"}). The mRNA levels of TNF-α and IL-1β were little different in the NMDA-, and KA-injected brain ([Fig. 2C](#f2-molcell-37-4-345-10){ref-type="fig"}), although these differences did not reach statistical significance. mRNA expression of iNOS increased to similar levels at 12 h to 1 day in both NMDA- and KA-injected cortexes ([Fig. 2C](#f2-molcell-37-4-345-10){ref-type="fig"}), suggesting that iNOS does not contribute to delayed neuronal death in the KA model. We also examined infiltration of myeloperoxidase-positive (MPO^+^) neutrophils, which could produce cytotoxic inflammatory mediators ([@b17-molcell-37-4-345-10]; [@b18-molcell-37-4-345-10]). At 1 day, MPO^+^ neutrophils were readily detectable in both core and penumbra regions of the KA-injected cortex, whereas much fewer neutrophils were detectable in only core regions in the NMDA-injected cortex (arrows in [Fig. 2D](#f2-molcell-37-4-345-10){ref-type="fig"}). Some neutrophils also expressed iNOS in both NMDA and KA models (arrows in [Fig. 2D](#f2-molcell-37-4-345-10){ref-type="fig"}). Relative levels of MPO and iNOS in intact, NMDA-, KA, and PBS-injected brain at 1 day after injection were quantified using Image J ([Fig. 2D](#f2-molcell-37-4-345-10){ref-type="fig"}). Although the number of MPO^+^ neutrophils in area 'b' slightly higher in KA-injected brain than in PBS-, and NMDA-injected brain ([Fig. 2D](#f2-molcell-37-4-345-10){ref-type="fig"}), neutrophils may not kill neurons in the KA model since LPS recruited many more neutrophils, but barely damaged neurons ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}), as we previously reported ([@b17-molcell-37-4-345-10]; [@b18-molcell-37-4-345-10]). Furthermore, iNOS levels were not different in PBS-, NMDA-, and KA-injected brain ([Fig. 2D](#f2-molcell-37-4-345-10){ref-type="fig"}). Therefore, neutrophils are not likely the cause of delayed neuronal death in the KA model. Taken together, these results suggest that there was little difference in inflammatory responses between KA- and NMDA-injected cortexes although the territories of microglial cell death and monocytes infiltration were different.

Severe astrocyte loss occurred in the KA-injected cortex
--------------------------------------------------------

Next, we examined whether astrocyte behavior was related to delayed neuronal death based on the hypothesis that neurons may not survive without the support of astrocytes, which maintain homeostasis of the brain microenvironment and supply nutrients and growth factors to neurons ([@b1-molcell-37-4-345-10]; [@b4-molcell-37-4-345-10]; [@b26-molcell-37-4-345-10]; [@b28-molcell-37-4-345-10]; [@b29-molcell-37-4-345-10]; [@b34-molcell-37-4-345-10]; [@b39-molcell-37-4-345-10]; [@b41-molcell-37-4-345-10]). Interestingly, the behavior of astrocytes demonstrated by several markers of astrocytes including GFAP, S100β, glutamate transporters (EAAT2; GLT-1), potassium channels (Kir4.1), and glutamate synthetase (GS) was different in NMDA and KA models ([Figs. 3](#f3-molcell-37-4-345-10){ref-type="fig"} and [4](#f4-molcell-37-4-345-10){ref-type="fig"}). GFAP^+^ astrocytes became swollen in the core and penumbra in the KA-injected brain at 3 h (black arrowheads in [Fig. 3A](#f3-molcell-37-4-345-10){ref-type="fig"}, regions 'a, b') compared with astrocytes in intact (black arrows in [Fig. 3A](#f3-molcell-37-4-345-10){ref-type="fig"}, regions 'a, b') and PBS-injected ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}) brains. In the KA-injected brain, GFAP^+^ astrocytes eventually disappeared starting at 1 day, and the GFAP^+^ astrocyte-absent area increased thereafter up to 7 days ([Fig. 3A](#f3-molcell-37-4-345-10){ref-type="fig"}). However, in the NMDA-injected cortex, GFAP^+^ astrocytes were disappeared in the injection site at 3 h ([Fig. 3A](#f3-molcell-37-4-345-10){ref-type="fig"}, region 'a'), but did not further disappeared between 1 and 7 days ([Fig. 3A](#f3-molcell-37-4-345-10){ref-type="fig"}, white dotted lines in region 'a' and white arrows in region 'b'). GFAP intensities in regions 'a' and 'b' in KA- and NMDA-injected brain at the indicated times were quantified ([Fig. 3A](#f3-molcell-37-4-345-10){ref-type="fig"}). It is noticeable that KA significantly decreased GFAP intensities in region 'b' at 1 and 7 days after the injection but NMDA did not ([Fig. 3A](#f3-molcell-37-4-345-10){ref-type="fig"}).

We obtained similar results using S100β, another marker of astrocytes. S100β^+^ astrocytes disappeared in the KA-injected hemisphere at 1--7 days ([Fig. 3B](#f3-molcell-37-4-345-10){ref-type="fig"}). Interestingly, S100β immunoreactivity rapidly decreased prior to GFAP immunoreactivity ([Fig. 3A](#f3-molcell-37-4-345-10){ref-type="fig"}, KA, 3 h vs. [Fig. 3B](#f3-molcell-37-4-345-10){ref-type="fig"}, KA, 3 h). Double labeling using anti-GAF and anti-S100β antibodies revealed that intact astrocytes co-expressed GFAP and S100β (white arrows in [Fig. 3C](#f3-molcell-37-4-345-10){ref-type="fig"}), whereas GFAP^+^ reactive astrocytes in the KA-injected cortex lost S100β immunoreactivity at 3 h (white arrowheads in [Fig. 3C](#f3-molcell-37-4-345-10){ref-type="fig"}). At 1 day, neither GFAP nor S100β immunoreactivity was detectable ([Fig. 3C](#f3-molcell-37-4-345-10){ref-type="fig"}). In the NMDA-injected cortex, S100β^+^ astrocytes disappeared in the injection site ([Fig. 3B](#f3-molcell-37-4-345-10){ref-type="fig"}, region 'a'), but remained in the peripheral region (black arrows in [Fig. 3B](#f3-molcell-37-4-345-10){ref-type="fig"}, region 'b'). In the PBS-injected brain, GFAP^+^ astrocytes exhibited a reactive morphology in the injection site, but showed no evidence of death ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). Most importantly, in the KA-injected cortex, the GFAP^+^ astrocyte-absent area exactly matched with that of delayed neuronal death ([Fig. 3D](#f3-molcell-37-4-345-10){ref-type="fig"}). These results suggest that loss of astrocyte support may be closely related to delayed neuronal death in the KA-injected cortex.

We further examined several functional markers of astrocytes in both NMDA- and KA-injected cortexes. EAAT2 (GLT-1) and Kir4.1 are known to be mainly expressed in astrocytes and to regulate extracellular glutamate and potassium concentration ([@b28-molcell-37-4-345-10]; [@b34-molcell-37-4-345-10]). GS is also expressed in astrocytes and catalyzes the formation of glutamine from glutamate and ammonia ([@b11-molcell-37-4-345-10]). Similar to GFAP^+^ astrocytes, EAAT2^+^, Kir4.1^+^ and GS^+^ astrocytes disappeared in almost the entire hemisphere 1 day after KA injection, but not after NMDA injection ([Fig. 4](#f4-molcell-37-4-345-10){ref-type="fig"}).

A more detailed analysis showed that EAAT2 immunoreactivity was present in the astrocyte processes around neuronal cell bodies in the intact brain (white arrows in [Fig. 4A](#f4-molcell-37-4-345-10){ref-type="fig"}). In the KA-injected cortex, EAAT2^+^ astrocytes were maintained at 3 h (white arrows in [Fig. 4A](#f4-molcell-37-4-345-10){ref-type="fig"}, regions 'a, b'), but subsequently disappeared at 1--7 days ([Fig. 4A](#f4-molcell-37-4-345-10){ref-type="fig"}). In the NMDA-injected cortex, EAAT2^+^ astrocytes began to disappear at 1 day in the damage core ([Fig. 4A](#f4-molcell-37-4-345-10){ref-type="fig"}, region 'a'), but remained for up to 7 d in the penumbra ([Fig. 4A](#f4-molcell-37-4-345-10){ref-type="fig"}, region 'b').

Kir4.1 immunoreactivity was detectable in the intact brain (white arrows in [Fig. 4B](#f4-molcell-37-4-345-10){ref-type="fig"}). In the KA-injected cortex, Kir4.1 immunoreactivity was increased slightly at 3 h in the damage core and penumbra (white arrowheads in [Fig 4B](#f4-molcell-37-4-345-10){ref-type="fig"}), but eventually disappeared beginning at 1 day ([Fig 4B](#f4-molcell-37-4-345-10){ref-type="fig"}). In the NMDA-injected core, Kir4.1^+^ astrocytes disappeared at 3 h and thereafter ([Fig. 4B](#f4-molcell-37-4-345-10){ref-type="fig"}, region 'a'), but Kir4.1 immunoreactivity increased in the penumbra region at 3 h and 7 days (white arrowheads in [Fig. 4B](#f4-molcell-37-4-345-10){ref-type="fig"}, region 'b').

GS immunoreactivity was also detectable in intact astrocytes (white arrows in [Fig. 4C](#f4-molcell-37-4-345-10){ref-type="fig"}). In the KA-injected cortex, GS^+^ astrocytes disappeared from 3 h to 7 days in both core and penumbra regions ([Fig. 4C](#f4-molcell-37-4-345-10){ref-type="fig"}, region 'a, b'). In the NMDA-injected brain, however, GS^+^ astrocytes disappeared only in the core, but GS immunoreactivity increased and/or maintained in astrocytes in the penumbra region at 3 h and thereafter ([Fig. 4C](#f4-molcell-37-4-345-10){ref-type="fig"}, region 'a, b'). EAAT2^+^, Kir4.1^+^, and GS^+^ astrocytes in the PBS-injected brain were similar to those in the intact brain (data not shown). Taken together, these results also show that loss of astrocyte function occurred in the KA model where delayed neuronal GFAP and NeuN antibodies showed that GFAP^+^ astrocytes and NeuN^+^ neurons were healthy in intact and PBS-injected brains ([Fig. 5A](#f5-molcell-37-4-345-10){ref-type="fig"}). However, in the KA-injected cortex, the intensity of dark purple-colored astrocytes decreased slightly at 3 h, making brown-colored neurons more obvious ([Fig. 5A](#f5-molcell-37-4-345-10){ref-type="fig"}). At 1 day, dark purple-colored astrocytes had almost disappeared, but neurons were still present, suggesting that disappearance of astrocytes precedes neuronal death in the KA-injected cortex (arrowheads in [Fig. 5A](#f5-molcell-37-4-345-10){ref-type="fig"}). We further examined whether the remaining neurons where astrocytes disappeared (black arrowheads in [Fig. 5A](#f5-molcell-37-4-345-10){ref-type="fig"}) were healthy. Intact NeuN^+^ neurons exhibited round cell bodies and homogenously stained DAPI^+^ nuclei (white arrows in [Fig. 5B](#f5-molcell-37-4-345-10){ref-type="fig"}). However, at 3 h, cell bodies and nuclei of most NeuN^+^ neurons in the core region had shrunk and/or showed DNA condensation (white arrowheads in [Fig. 5B](#f5-molcell-37-4-345-10){ref-type="fig"}, region 'a'). In the penumbra region, most NeuN^+^ neurons still had intact nuclei at 3 h (white arrows in [Fig. 5B](#f5-molcell-37-4-345-10){ref-type="fig"}, region 'b'), but at 1 day, the remaining faintly stained NeuN^+^ neurons were shrunken and showed DNA condensation, as in the core region (white arrowheads in [Fig. 5B](#f5-molcell-37-4-345-10){ref-type="fig"}, regions 'a, b'). Double labeling using NeuN and GS antibodies also showed that the functional loss of astrocytes preceded neuronal death. In the intact brain, NeuN^+^ neurons and GS^+^ astrocytes coexisted ([Fig. 5C](#f5-molcell-37-4-345-10){ref-type="fig"}). However, at 3 h after KA injection, GS^+^ astrocytes rapidly disappeared in 'a' and 'b' regions whereas NeuN^+^ neurons remained ([Fig. 5C](#f5-molcell-37-4-345-10){ref-type="fig"}). Taken together, these results suggest that loss of neuron-supportive astrocytes eventually led to delayed neuronal death.

Astrocyte functional loss preceded delayed neuronal death in the KA-injected cortex
-----------------------------------------------------------------------------------

Previously, we reported that delayed neuronal death in contusion-induced spinal cord injury is spatially and temporally correlated with astrocyte death, suggesting that loss of astrocyte function may be critical for delayed neuronal death ([@b25-molcell-37-4-345-10]). In this study, we investigated a possible correlation between progressive degeneration of astrocytes and delayed neuronal cell death in the KA model. Double labeling using GFAP and NeuN antibodies showed that GFAP^+^ astrocytes and NeuN^+^ neurons were healthy in intact and PBS-injected brains ([Fig. 5A](#f5-molcell-37-4-345-10){ref-type="fig"}). However, in the KA-injected cortex, the intensity of dark purple-colored astrocytes decreased slightly at 3 h, making brown-colored neurons more obvious ([Fig. 5A](#f5-molcell-37-4-345-10){ref-type="fig"}). At 1 day, dark purple-colored astrocytes had almost disappeared, but neurons were still present, suggesting that disappearance of astrocytes precedes neuronal death in the KA-injected cortex (arrowheads in [Fig. 5A](#f5-molcell-37-4-345-10){ref-type="fig"}). We further examined whether the remaining neurons where astrocytes disappeared (black arrowheads in [Fig. 5A](#f5-molcell-37-4-345-10){ref-type="fig"}) were healthy. Intact NeuN^+^ neurons exhibited round cell bodies and homogenously stained DAPI^+^ nuclei (white arrows in [Fig. 5B](#f5-molcell-37-4-345-10){ref-type="fig"}). However, at 3 h, cell bodies and nuclei of most NeuN^+^ neurons in the core region had shrunk and/or showed DNA condensation (white arrowheads in [Fig. 5B](#f5-molcell-37-4-345-10){ref-type="fig"}, region 'a'). In the penumbra region, most NeuN^+^ neurons still had intact nuclei at 3 h (white arrows in [Fig. 5B](#f5-molcell-37-4-345-10){ref-type="fig"}, region 'b'), but at 1 day, the remaining faintly stained NeuN^+^ neurons were shrunken and showed DNA condensation, as in the core region (white arrowheads in [Fig. 5B](#f5-molcell-37-4-345-10){ref-type="fig"}, regions 'a, b'). Double labeling using NeuN and GS antibodies also showed that the functional loss of astrocytes preceded neuronal death. In the intact brain, NeuN^+^ neurons and GS^+^ astrocytes coexisted ([Fig. 5C](#f5-molcell-37-4-345-10){ref-type="fig"}). However, at 3 h after KA injection, GS^+^ astrocytes rapidly disappeared in 'a' and 'b' regions whereas NeuN^+^ neurons remained ([Fig. 5C](#f5-molcell-37-4-345-10){ref-type="fig"}). Taken together, these results suggest that loss of neuron-supportive astrocytes eventually led to delayed neuronal death.

Astrogliosis appeared to protect neurons from further damage in the NMDA-injected cortex
----------------------------------------------------------------------------------------

Finally, we examined whether the absence of delayed neuronal death in the NMDA-injected brain was due to survival of astrocytes. As shown above ([Figs. 1](#f1-molcell-37-4-345-10){ref-type="fig"} and [3](#f3-molcell-37-4-345-10){ref-type="fig"}), both astrocytes and neurons died in the core at 3 h after injection. In further analysis of behavior of astrocytes and neurons, we found that at 3 h, atrocyte-absent areas were much smaller than neuron-death areas (red lines in [Figs. 6A and 6B](#f6-molcell-37-4-345-10){ref-type="fig"}), and astrocytes outside of the dead areas underwent gliosis, as confirmed by an increase in GFAP expression levels ([Fig. 6A](#f6-molcell-37-4-345-10){ref-type="fig"}). Astrocyte gliosis continued to progress at 7 days, and neurons were healthy in areas where gliosis occurred (red lines in [Figs. 6A, 6B, and 6C](#f6-molcell-37-4-345-10){ref-type="fig"}). Taken together with our demonstration that surviving astrocytes in the NMDA-injected brain highly expressed not only GFAP but several functional markers, including EAAT1, Kir4.1 and GS ([Fig. 3](#f3-molcell-37-4-345-10){ref-type="fig"}), these results suggest that astrogliosis may be a mechanism for protecting neurons in the injured brain. Therefore, neuronal death could be caused by the death and/or loss of function of astrocytes required to support neuronal survival.

DISCUSSION
==========

In this study, we showed that 1) KA injection, but not NMDA injection, induced delayed neuronal death, but there was little difference in inflammatory responses between KA- and NMDA-injected cortexes; 2) extensive astrocyte loss occurred in the KA-injected cortex; 3) the astrocyte loss territory correlated with the delayed neuronal damage area in the KA-injected cortex; and 4) the disappearance of astrocyte markers preceded delayed neuronal death in the KA-injected cortex. On the basis of these findings, we suggest that loss of astrocyte support is a critical cause of delayed neuronal death in the injured brain.

Many studies have reported that brain inflammation is neurotoxic and aggravates progressive neuronal death in neurode-generative diseases ([@b3-molcell-37-4-345-10]; [@b6-molcell-37-4-345-10]; [@b9-molcell-37-4-345-10]; [@b20-molcell-37-4-345-10]; [@b35-molcell-37-4-345-10]; [@b36-molcell-37-4-345-10]). However, we and others have reported that brain inflammation is not neurotoxic but is instead neuroprotective and functions to repair the injured brain ([@b2-molcell-37-4-345-10]; [@b7-molcell-37-4-345-10]; [@b12-molcell-37-4-345-10]; [@b13-molcell-37-4-345-10]; 2013a; 2013b; [@b22-molcell-37-4-345-10]; [@b23-molcell-37-4-345-10]; [@b24-molcell-37-4-345-10]; [@b25-molcell-37-4-345-10]; [@b30-molcell-37-4-345-10]; [@b37-molcell-37-4-345-10]; [@b42-molcell-37-4-345-10]; [@b43-molcell-37-4-345-10]; [@b44-molcell-37-4-345-10]). In this study, we demonstrated that inflammatory responses were similar in both KA-and NMDA-injected cortexes. Regardless of the presence or absence of delayed neuronal death, resident microglia died at 3 h and monocytes infiltrated at 7 days after KA or NMDA injection ([Fig. 2](#f2-molcell-37-4-345-10){ref-type="fig"}). Quantitative mRNA expression analyses showed that TNF-α and IL-1β significantly increased at 12 h in both NMDA- and KA-injected cortexes ([Fig. 2B](#f2-molcell-37-4-345-10){ref-type="fig"}) compared to cortexes injected with PBS, although TNF-α and IL-1β levels were slightly elevated in the NMDA- and KA-injected cortex, respectively ([Fig. 2](#f2-molcell-37-4-345-10){ref-type="fig"}). In addition, infiltration of neurotoxic iNOS-expressing neutrophils was very low in both NMDA- and KA-injected brains, and iNOS levels were similarly increased at 12 h to 1 day in both NMDA- and KA-injected cortexes ([Fig. 2](#f2-molcell-37-4-345-10){ref-type="fig"}). Therefore, inflammatory responses appeared to have little effect on delayed neuronal death in the KA-injected brain.

It is well known that astrocytes regulate the brain microenvironment and support neurons by supplying glucose and neurotrophic factors, regulating oxidative stress and excitotoxicity through glutathione (GSH) production and uptake of glutamate and potassium, and regulating extracellular water content ([@b1-molcell-37-4-345-10]; [@b4-molcell-37-4-345-10]; [@b26-molcell-37-4-345-10]; [@b28-molcell-37-4-345-10]; [@b29-molcell-37-4-345-10]; [@b34-molcell-37-4-345-10]; [@b39-molcell-37-4-345-10]; [@b41-molcell-37-4-345-10]). Thus, astrocyte support is required for neuronal survival ([@b16-molcell-37-4-345-10]; [@b25-molcell-37-4-345-10]). A loss of EAAT2/GLT-1 and decreased glutamate transport have been identified in human ALS patients ([@b32-molcell-37-4-345-10]; [@b33-molcell-37-4-345-10]). In addition, astrocyte functional loss precedes neuronal death in spinal cord injury ([@b25-molcell-37-4-345-10]), and transplantation of human astrocytes facilitates functional recovery after the injury ([@b8-molcell-37-4-345-10]; [@b27-molcell-37-4-345-10]). In the previous study, we showed that in ATP-injected brain, astrogliosis occurs and delayed neuronal death is absent ([@b16-molcell-37-4-345-10]). The results presented in the current study also showed that neuronal death is closely linked to astrocyte loss. Notably, astrocytes gradually disappeared throughout the entire hemisphere at 7 days in the KA-injected cortex, whereas astrocyte disappearance was confined to the injection core in the NMDA-injected cortex at 7 days ([Figs. 1](#f1-molcell-37-4-345-10){ref-type="fig"} and [3](#f3-molcell-37-4-345-10){ref-type="fig"}). Moreover, only the KA-injected cortex showed an extensive disappearance of proteins important for astrocyte function, such as EAAT2, Kir4.1 and GS, throughout the hemisphere ([Fig. 4](#f4-molcell-37-4-345-10){ref-type="fig"}). Accordingly, GFAP+ as well as S100β^+^ and GS^+^ astrocytes disappeared at 1 day, before the death of NeuN^+^ neurons ([Fig. 5](#f5-molcell-37-4-345-10){ref-type="fig"} and [Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). Another important feature of the NMDA-injected brain was astrogliosis (reactive astrocytes) in the penumbra region ([Fig. 6](#f6-molcell-37-4-345-10){ref-type="fig"}) where neurons were healthy ([Fig. 1](#f1-molcell-37-4-345-10){ref-type="fig"}). Therefore, the territories of loss of astrocyte support correlated with the neuron-damaged area in both NMDA- and KA-injected cortexes ([Figs. 1](#f1-molcell-37-4-345-10){ref-type="fig"} and [3](#f3-molcell-37-4-345-10){ref-type="fig"}), indicating that reactive astrocytes protect neurons in the injured brain as previously reported in several brain injury models ([@b8-molcell-37-4-345-10]; [@b10-molcell-37-4-345-10]; [@b27-molcell-37-4-345-10]; [@b32-molcell-37-4-345-10]; 1995; [@b38-molcell-37-4-345-10]; [@b45-molcell-37-4-345-10]).

The discrepancy between astrocyte behavior in the NMDA-and KA-injected brain may reflect differences in the expression levels of NMDA receptors and KA receptors in astrocytes. Astrocytes rarely express NMDA receptors ([@b21-molcell-37-4-345-10]). Thus, NMDA does not induce astrocyte cell death. On the other hand, astrocytes are vulnerable to KA ([@b5-molcell-37-4-345-10]). Therefore, differences in the vulnerability of astrocytes to NMDA and KA appear to determine the absence and presence of delayed neuronal death.

In conclusion, astrocyte functional loss may be a critical cause of delayed neuronal death in the injured brain. Our results highlight the physiological importance of astrocytes in protecting neurons from a harmful microenvironment. Therefore, preservation of astrocytes and/or astrocyte functional support could be a therapeutic strategy for preventing delayed neuronal death in the injured brain.
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![Neurons underwent extensive cell death in the KA-injected cortex, but not in the NMDA-injected cortex. (A, B, and C) Cortical brain sections (30 μm thickness) were obtained at the indicated times after injection of 100 nmole NMDA (in 2 μl PBS), 20 nmole KA, or PBS, and every sixth serial section was selected, labeled with NeuN antibodies, and visualized with peroxidase-conjugated secondary antibodies. Photographs of the most damaged sections were taken. The number of animals used in this study was at least 5 for each drug (PBS, NMDA, and KA) and each time point. (A, B, and C) Lower panels are higher magnification images of boxed areas in regions 'a' (core) and 'b' (penumbra) in upper panels. NeuN^+^ neuronal loss was detected in only the core region at 3 h to 7 days in the NMDA-injected cortex (B), but in both core and penumbra regions in the KA-injected cortex (C). Asterisks (\*) indicate drug injection sites. Scale bars = 1 mm (upper panels) and 50 μm (lower panels). (D) Using Image J, NeuN-negative areas in the most damaged sections from at least 3 different animals were quantified at the indicated times. Values are means ± SEMs of more than three samples (^\*^p \< 0.01; ^\*\*^p \< 0.001).](molcell-37-4-345-10f1){#f1-molcell-37-4-345-10}

![Similar inflammatory responses occurred in NMDA- and KA-injected brains. (A, D) Sections were obtained from intact brain (I) or at the indicated times after NMDA (N), KA (K), or PBS (P) injection were labeled with primary antibodies against Iba-1 (A), MPO (D), or iNOS (D) and visualized using peroxidase-conjugated secondary antibodies. Photographs of the most damaged sections were taken. Lower panels are higher magnification images of boxed areas in upper panels. Dotted lines indicate neuron damage areas. \*, drug injection sites. (B) Relative Iba-1 intensities were measured using Image J as described in [Fig. 1](#f1-molcell-37-4-345-10){ref-type="fig"}. (C) Quantitative analysis of mRNA expression of inflammatory mediators. At the indicated times after NMDA, KA, or PBS injection, tissue blocks were obtained and TNF-α, IL-1β, and iNOS mRNA levels were analyzed using Q-PCR. Values (B, C, and D) are means ± SEMs of more than three samples (\*p \< 0.01; \*\*p \< 0.001). Scale bars = 1 mm \[upper panels in (A, D)\] and 50 μm \[lower panels in (A, D)\].](molcell-37-4-345-10f2){#f2-molcell-37-4-345-10}

![Extensive loss of GFAP+- and S100β^+^-astrocyte occurred in the KA-injected brain but not in the NMDA-injected brain. (A, B) Sections were obtained at the indicated times after NMDA or KA injection, labeled with primary antibodies against GFAP (A) or S100β (B), and visualized using peroxidase-conjugated secondary antibodies. \*, drug injection sites. Photographs of the most damaged sections were taken. Relative intensities of GFAP (A) and S100β (B) were measured using Image J and plotted. (A) In the KA-injected brain, GFAP+ astrocytes became swollen at 3 h (arrowheads) compared to intact GFAP^+^ astrocytes (arrows), and disappeared at 1 day. In the NMDA-injected brain, GFAP^+^ astrocytes disappeared in the core region at 3 h and 1 day, but were healthy in the penumbra region for up to 7 days (arrows). Dotted lines in the NMDA model at 3 h and 1 day indicate neuron damage areas. (B) S100β^+^ cells rapidly disappeared (3 h) and did not reappear in both KA-and NMDA-injection cores. However, in the penumbra region, S100β^+^ cells were not detected in the KA model, but in the NMDA model, they were as healthy as they were in the intact brain (black arrows). (C) Brain sections obtained at 3 h and 1 day were double labeled with GFAP and S100β antibodies, and visualized using Alexa Fluor 488- and 555-conjugated antibodies, respectively. In the intact cortex, GFAP^+^ cells were co-labeled with S100β (white arrows). S100β immunoreactivity disappeared at 3 h, which was earlier than the disappearance of GFAP^+^ immunoreactivity (white arrowheads). (D) Astrocyte- and neuron-negative areas were compared by staining immediately adjacent serial sections with GFAP and NeuN antibodies. Dotted lines indicate the borders where GFAP^+^ and NeuN+ cells were absent. Scale bars = 1 mm \[upper panels in (A, D)\], 50 μm (C), and 20 μm \[lower panels in (A)\]. Values are means ± SEMs of more than three samples (\*p \< 0.01; \*\*p \< 0.001). n.s, not significant.](molcell-37-4-345-10f3){#f3-molcell-37-4-345-10}

![Astrocyte functional loss was severe in the KA-injected brain but not in the NMDA-injected brain. Sections obtained at the indicated times after NMDA or KA injection were labeled with primary antibodies against EAAT2 (A), Kir4.1 (B) or GS (C), and visualized using peroxidase-conjugated secondary antibodies. Relative intensities of EAAT2 (A), Kir4.1 (B) or GS (C) were measured using Image J and plotted. Lower panels are higher magnification images of upper panels. EAAT2 (A), Kir4.1 (B) and GS (C) all showed similar patterns, although EAAT2 was detected in the astrocyte processes (white arrows in A) that surround neuronal cell bodies (N), and Kir4.1 and GS were detected in the astrocyte cell bodies \[white arrows and (B, C), respectively\]. In the core region, EAAT2 (A), Kir4.1 (B) and GS (C) entirely disappeared from 3 h and/or 1 d after injection in both KA- and NMDA-injected brains. In the penumbra region, all three functional markers disappeared in the KA-injected brain beginning after 3 h and/or 1 day, but were unchanged \[EAAT2, white arrows in (A)\] or slightly increased \[Kir4.1 and GS, white arrowheads in (B, C)\] in the NMDA-injected brain. Scale bars = 1 mm (upper panels) and 20 μm (lower panels). Values are means ± SEMs of more than three samples (^\*^p \< 0.01; ^\*\*^p \< 0.001). n.s, not significant.](molcell-37-4-345-10f4){#f4-molcell-37-4-345-10}

![Astrocyte loss preceded delayed neuronal death in the KA-injected cortex. (A) Brain sections were double labeled with primary antibodies against NeuN and GFAP, and visualized using peroxidaseconjugated secondary antibodies. Color reactions used DAB for NeuN (brown) and DAB/nickel sulfate for GFAP (dark purple). In intact and PBS-injected brains, GFAP^+^ astrocytes and NeuN^+^ neurons were labeled. At 3 h GFAP immunoreactivity slightly decreased in the KA-injected brain, although both types of cells were detected. However, at 1 day, most GFAP^+^ astrocytes disappeared whereas NeuN^+^ neurons were still present (black arrowheads). (B, C) Brain sections obtained at the indicated times after KA injection were labeled with antibodies against NeuN (B), NeuN and GS (C), and visualized using Alexa Fluor 488- and/or 555-conjugated antibodies. Nuclei were labeled with DAPI. (B) Intact NeuN^+^ neurons exhibited round cell bodies and homogenously stained DAPI^+^ nuclei (black arrows). Shrunken and/or condensed neurons (white arrows) were detected in the core region at 3 h, and in both core and penumbra regions at 1 day. (C) At 3 h after injection, GS^+^ astrocytes (white arrows) disappeared, whereas NeuN+ neurons were still present in both 'a' and 'b' regions. At 1 day, GS^+^ astrocytes had completely disappeared, and shrunken NeuN+ neurons (white arrowheads) were detectable. Scale bars = 1 mm \[upper panels in (A)\], 50 μm \[lower panels in (A), and (C)\], and 20 μm (B).](molcell-37-4-345-10f5){#f5-molcell-37-4-345-10}

![Neurons were healthy in the NMDA-injected cortex where astrogliosis occurred. (A, B) Locations of GFAP-labeled astrocytes and NeuN-labeled neurons were analyzed in brain sections obtained at 3 h and 7 days after NMDA injection. Lower panels are higher magnification of boxed areas in upper panels. \*, drug injection sites. Insets in lower panels in (A) indicate higher magnification of dotted boxes. At 3 h after NMDA injection, GFAP expression significantly increased compared to the intact brain, and processes became thicker. At 7 days, GFAP expression further increased. (C) Notably, neurons were healthy in areas where astrogliosis occurred. Red dotted lines in (A, B, and C) indicate the borders of dead- and live-neuron areas. Scale bars = 1 mm \[upper panels in (A, B)\], 100 μm \[lower panels in (A, B)\], and 20 μm \[inset in lower panels in (A), and (C)\].](molcell-37-4-345-10f6){#f6-molcell-37-4-345-10}

###### 

Information for primary antibodies used in immunohistochemistry

  Protein   Dilution   Company
  --------- ---------- -----------------------
  EAAT2     1:500      Abcam
  GFAP      1:700      Sigma
  GS        1:500      BD Biosciences
  Iba-1     1:1000     Wako
  iNOS      1:200      Upstate Biotechnology
  Kir4.1    1:800      Alomone
  MPO       1:1000     Dako
  NeuN      1:300      Millipore
  S100β     1:500      Abcam
  S100β     1:800      Swant

###### 

List of primer sequences for Q-PCR

  ----------------------------------
  Gene    Sequence (5′-3′)
  ------- --------------------------
  IL-1β   F: TGATGTTCCCATTAGACAGC\
          R: GAGGTGCTGATGTACCAGTT

  TNF-α   F: GTAGCCCACGTCGTAGCAAA\
          R: CCCTTCTCCAGCTGGGAGAC

  iNOS    F: GCAGAATGTGACCATCATGG\
          R: ACAACCTTGGTGTTGAAGGC

  GAPDH   F: TCCCTCAAGATTGTCAGCAA\
          R: AGATCCACAACGGATACATT
  ----------------------------------

F, Forward primer; R, Reverse primer
